Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vilanterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928189 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL118138 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29352123 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL17031687 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL142630 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL15614685 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Acetic Acid SCHEMBL925230 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL925229 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29448201 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL19236014 | 0.94 | ADRB2 (0.88) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453727-B2 | Montelukast salts and pharmaceutical compositions containing the same | GENETIC S.P.A. (IT) | 2025-10-28 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220218690-A1 | MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GENETIC S.P.A. (IT) | 2022-07-14 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453727-B2 | Montelukast salts and pharmaceutical compositions containing the same | ADRB2, CYSLTR2, LTB4R2 | ADRB2 1/4885ADRB1 4/4885SLC6A2 1971/4885 |
| US-20220218690-A1 | MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADRB2, CYSLTR2, LTB4R2 | ADRB2 1/4885ADRB1 4/4885SLC6A2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.